{
    "root": "f69829a1-dd63-4a2e-9511-65fcd446bbf1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "risperidone",
    "value": "20250506",
    "ingredients": [
        {
            "name": "RISPERIDONE",
            "code": "L6UH7ZF8HC"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C YELLOW NO. 6 ALUMINUM LAKE",
            "code": "GYP6Z2JR6Q"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "FD&C BLUE NO. 2 ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "INDIGOTINDISULFONATE SODIUM",
            "code": "D3741U8K7L"
        }
    ],
    "indications": "Risperidone is an atypical antipsychotic indicated for: • Treatment      of schizophrenia ( 1.1 ) • As      monotherapy or adjunctive therapy with lithium or valproate, for the      treatment of acute manic or mixed episodes associated with Bipolar I      Disorder ( 1.2 ) • Treatment      of irritability associated with autistic disorder ( 1.3 )",
    "contraindications": "Table 1 Recommended Daily Dosage by Indication \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              \n                                  Initial Dose \n                                 \n                              \n                           \n                           \n                              \n                                  Titration \n                                 \n                                  (Increments) \n                                 \n                              \n                           \n                           \n                              \n                                  Target Dose \n                                 \n                              \n                           \n                           \n                              \n                                  Effective Dose \n                                 \n                                  Range \n                                 \n                              \n                           \n                        \n                        \n                           \n                               Schizophrenia: adults (2.1) \n                              \n                           \n                           \n                               2 mg\n                              \n                           \n                           \n                               1 to 2 mg\n                              \n                           \n                           \n                               4 to 8 mg\n                              \n                           \n                           \n                               4 to 16 mg\n                              \n                           \n                        \n                        \n                           \n                               Schizophrenia:  adolescents  (2.2) \n                              \n                           \n                           \n                               0.5 mg\n                              \n                           \n                           \n                               0.5 to 1 mg\n                              \n                           \n                           \n                               3 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                        \n                        \n                           \n                               Bipolar mania: adults (2.2) \n                              \n                           \n                           \n                               2 to 3 mg\n                              \n                           \n                           \n                               1 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                        \n                        \n                           \n                               Bipolar mania:  children and  adolescents  (2.2) \n                              \n                           \n                           \n                               0.5 mg\n                              \n                           \n                           \n                               0.5 to 1 mg\n                              \n                           \n                           \n                               1 to 2.5 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                        \n                        \n                           \n                               Irritability in autistic  disorder (2.3) \n                              \n                           \n                           \n                               0.25 mg Can increase to 0.5 mg by Day 4: (body weight less than 20 kg) 0.5 mg Can increase to 1 mg by Day 4: (body weight greater than or equal to 20 kg)\n                              \n                           \n                           \n                               After Day 4, at intervals of > 2 weeks: 0.25 mg (body weight less than 20 kg) 0.5 mg (body weight greater than or equal to 20 kg)\n                              \n                           \n                           \n                               0.5 mg: (body weight less than 20 kg) 1 mg: (body weight greater than or equal to 20 kg)\n                              \n                           \n                           \n                               0.5 to  3 mg\n                              \n                           \n                        \n                     \n                  \n                  Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily.\n                  May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.",
    "warningsAndPrecautions": "Risperidone Tablets USP, 0.25 mg are dark yellow, round, biconvex film-coated tablets debossed with \"Z\" on one side and \"4\" on the other side and are supplied as follows:\n                        Cartons of 100 film-coated tablets (10 film-coated tablets each blister pack x 10), NDC 0904-7360-61 \n                        Risperidone Tablets USP, 0.5 mg are red-brown colored, round, biconvex film-coated tablets debossed with \"Z\" on one side and \"6\" on other side and are supplied as follows:\n                        Cartons of 100 film-coated tablets (10 film-coated tablets each blister pack x 10), NDC 0904-7361-61\n                        Risperidone Tablets USP, 1 mg are white to off-white, round, biconvex film-coated tablets debossed with \"ZC 75\" on one side and plain on other side and are supplied as follows:\n                        Cartons of 100 film-coated tablets (10 film-coated tablets each blister pack x 10), NDC 0904-7362-61\n                        Risperidone Tablets USP, 2 mg are orange, round, biconvex film-coated tablets debossed with \"ZC 76\" on one side and plain on other side and are supplied as follows:\n                        Cartons of 100 film-coated tablets (10 film-coated tablets each blister pack x 10), NDC 0904-7363-61\n                        Risperidone Tablets USP, 3 mg are yellow, round, biconvex film-coated tablets debossed with \"ZC 77\"on one side and plain on other side and are supplied as follows:\n                        Cartons of 100 film-coated tablets (10 film-coated tablets each blister pack x 10), NDC 0904-7364-61\n                        Risperidone Tablets USP, 4 mg are green, round, biconvex film-coated tablets debossed with \"ZC 78\" on one side and plain on other side and are supplied as follows:\n                        Cartons of 100 film-coated tablets (10 film-coated tablets each blister pack x 10), NDC 0904-7365-61",
    "adverseReactions": "Risperidone is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the risperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone."
}